Lysophospholipids, exemplified by lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), are produced by the metabolic breakdown of membrane phospholipids. In vertebrates, LPA and S1P act in the extracellular environment as agents of cell-cell communication and stimulate specific G protein-coupled receptors. This signaling system is extremely widespread and regulate embryonic development and normal physiological processes of almost all organ systems. In addition, dysregulation of LPA and S1P signaling systems contribute to many disease processes. Indeed, several lysophospholipid receptor modulators have been approved for use in the treatment of autoimmune diseases and several more are under clinical testing. The exponential growth of this field of research is due in part to seminal discoveries and technologies that enable basic research findings. This volume aims to feature critical research technologies in the lysophospholipid research field as well as emerging technologies to address important questions and future challenges.
A stably established two-point injection lysophosphatidylcholine-induced focal demyelination model in mice
Daishi Tian*1
1Department of Neurology, Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology